Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Cancer Discov. 2020 Jul 22;10(11):1645–1653. doi: 10.1158/2159-8290.CD-20-0300

Figure 1. Persistence of transgenic TCR DNA and RNA/protein expression of TCR-engineered T-cells over time.

Figure 1.

A) Comparison between infusion products (day 0) and post-infusion recovery products 70 days later from patients on NYESO-1 TCR-engineered cell therapy trials (ESO and INY) or F5-MART-1 TCR-engineered cell therapy trial (F5). Data displayed are percentage of cells containing the transgenic TCR DNA sequence via TCR sequencing (red, left axis), the percentage of cells expressing the TCR protein via MHC dextramer FACS (green, left axis), and the relative level of RNA transcript via qRT-PCR (blue, right axis). Inset boxed patients represent those with surface TCR expression <0.5% at day +70. B, C, D) Statistical comparisons between expression-high and expression-low patient cohorts demonstrating no significant differences between day +70 transgenic TCR DNA (B), while surface protein expression (C) and relative RNA level (D) at day +70 are significantly lower in the expression-low cohort (** p<0.01, ***p<0.001, Mann-Whitney U test).